Hans Gelderblom Selected Research

ripretinib

12/2021	Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study.
11/2021	Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study.
1/2021	Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour.
10/2020	Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib.
1/2020	Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib.
1/2020	Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hans Gelderblom Research Topics

Disease

125	Neoplasms (Cancer) 01/2022 - 01/2002
52	Sarcoma (Soft Tissue Sarcoma) 07/2022 - 07/2008
26	Colorectal Neoplasms (Colorectal Cancer) 10/2021 - 01/2009
22	Osteosarcoma (Osteogenic Sarcoma) 10/2022 - 04/2011
20	Neoplasm Metastasis (Metastasis) 01/2022 - 09/2005
18	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 05/2022 - 07/2008
16	Disease Progression 10/2022 - 06/2012
14	Breast Neoplasms (Breast Cancer) 02/2021 - 06/2003
11	Ewing Sarcoma (Sarcoma, Ewing) 01/2022 - 09/2011
9	Nausea 01/2021 - 09/2009
9	Renal Cell Carcinoma (Grawitz Tumor) 01/2018 - 02/2011
8	Hypertension (High Blood Pressure) 12/2021 - 06/2008
8	Fatigue 01/2021 - 09/2003
8	Prostatic Neoplasms (Prostate Cancer) 01/2020 - 05/2013
8	Chondrosarcoma 01/2020 - 03/2008
6	Giant Cell Tumor of Tendon Sheath 11/2021 - 03/2012
6	Vomiting 01/2021 - 02/2011
6	Neutropenia 04/2014 - 11/2008
5	Alopecia (Baldness) 08/2022 - 09/2003
5	Liposarcoma 07/2022 - 01/2014
5	Colonic Neoplasms (Colon Cancer) 10/2021 - 04/2004
5	Adrenocortical Carcinoma 01/2021 - 04/2011
5	Giant Cell Tumor of Bone 01/2019 - 01/2016
4	Giant Cell Tumors (Giant Cell Tumor) 01/2022 - 06/2015
4	Dihydropyrimidine Dehydrogenase Deficiency 01/2022 - 07/2015
4	Leiomyosarcoma 01/2020 - 01/2016
4	Carcinogenesis 01/2017 - 02/2007
3	Body Weight (Weight, Body) 01/2021 - 08/2010
3	Stomatitis 01/2020 - 01/2012
3	Mesenchymal Chondrosarcoma 01/2019 - 03/2008
3	Ototoxicity 01/2019 - 01/2014
3	Thyroid Neoplasms (Thyroid Cancer) 01/2017 - 12/2009
3	Inflammation (Inflammations) 01/2017 - 12/2004

Drug/Important Bio-Agent (IBA)

22	Tyrosine Kinase InhibitorsIBA 05/2022 - 02/2007
22	Imatinib Mesylate (Gleevec)FDA Link 05/2022 - 12/2007
22	Pharmaceutical PreparationsIBA 01/2022 - 06/2003
17	Sunitinib (Sutent)FDA Link 02/2021 - 09/2009
16	pazopanib FDA Link 12/2021 - 01/2012
15	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2020 - 03/2012
11	Biomarkers (Surrogate Marker)IBA 06/2022 - 09/2005
11	Ifosfamide FDA LinkGeneric 01/2021 - 01/2014
11	Cisplatin (Platino)FDA LinkGeneric 01/2019 - 04/2011
8	Paclitaxel (Taxol)FDA LinkGeneric 08/2022 - 01/2002
8	Denosumab FDA Link 01/2020 - 06/2015
8	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2020 - 03/2009
8	Capecitabine (Xeloda)FDA Link 11/2018 - 03/2009
7	Irinotecan (Camptosar)FDA LinkGeneric 01/2022 - 11/2005
7	pexidartinibIBA 11/2021 - 10/2019
7	ErbB Receptors (EGF Receptor)IBA 10/2021 - 01/2011
7	Tamoxifen FDA LinkGeneric 01/2021 - 01/2009
7	Fluorouracil (Carac)FDA LinkGeneric 01/2021 - 04/2004
7	Docetaxel (Taxotere)FDA Link 01/2020 - 09/2014
7	Cetuximab (Erbitux)FDA Link 01/2018 - 07/2010
7	Proteins (Proteins, Gene)FDA Link 01/2018 - 07/2004
6	Melphalan (Alkeran)FDA LinkGeneric 01/2022 - 07/2008
6	DNA (Deoxyribonucleic Acid)IBA 12/2021 - 01/2009
6	ripretinibIBA 12/2021 - 01/2020
5	AnthracyclinesIBA 01/2022 - 04/2016
5	Mitotane (Lysodren)FDA Link 01/2021 - 04/2011
5	Biological ProductsIBA 07/2020 - 05/2010
5	Bevacizumab (Avastin)FDA Link 10/2019 - 01/2009
5	Cytochrome P-450 CYP2D6 (CYP2D6)IBA 10/2019 - 01/2009
5	Etoposide (VP 16)FDA LinkGeneric 09/2018 - 06/2012
4	exemestane (Aromasin)FDA Link 01/2021 - 07/2011
4	Phosphotransferases (Kinase)IBA 01/2021 - 02/2007
4	4-hydroxy-N-desmethyltamoxifenIBA 01/2020 - 11/2013
4	AntibodiesIBA 01/2018 - 09/2011
4	telatinibIBA 01/2018 - 06/2008
4	Insulin-Like PeptidesIBA 01/2017 - 09/2011
3	UracilIBA 01/2022 - 07/2015
3	Circulating Tumor DNAIBA 12/2021 - 03/2018
3	ParaffinIBA 01/2021 - 09/2016
3	EnzymesIBA 01/2021 - 01/2014
3	Dihydrouracil Dehydrogenase (NADP) (Dihydropyrimidine Dehydrogenase)IBA 01/2021 - 07/2015
3	Formaldehyde (Formol)FDA Link 01/2021 - 09/2016
3	Estrogens (Estrogen)FDA Link 01/2021 - 07/2011
3	spartalizumabIBA 01/2021 - 01/2020
3	Monoclonal AntibodiesIBA 10/2020 - 09/2011
3	Dacarbazine (DIC)FDA LinkGeneric 01/2020 - 04/2016
3	Methotrexate (Mexate)FDA LinkGeneric 01/2020 - 07/2015
3	Gemcitabine FDA Link 01/2020 - 01/2018
3	Diphosphonates (Bisphosphonates)IBA 01/2019 - 09/2005
3	TrabectedinIBA 01/2019 - 01/2017
3	Zoledronic Acid (Zometa)FDA Link 01/2019 - 01/2016
3	Cytochrome P-450 CYP3AIBA 01/2019 - 12/2004
3	Vincristine (Oncovin)FDA LinkGeneric 09/2018 - 11/2015
3	HLA-G Antigens (HLA G)IBA 01/2018 - 09/2016
3	TOR Serine-Threonine KinasesIBA 01/2017 - 01/2012
3	PanobinostatIBA 10/2016 - 11/2014
3	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2016 - 06/2008

Therapy/Procedure

67	Therapeutics 06/2022 - 12/2004
56	Drug Therapy (Chemotherapy) 10/2022 - 03/2008
18	Radiotherapy 07/2022 - 03/2008
10	Neoadjuvant Therapy 01/2022 - 06/2013
7	Adjuvant Chemotherapy 01/2020 - 02/2010
5	Aftercare (After-Treatment) 01/2021 - 09/2005
4	Castration 01/2020 - 09/2013
4	Drug Tapering 01/2020 - 08/2015
4	Induction Chemotherapy 01/2020 - 07/2015
3	Immunotherapy 01/2022 - 01/2012